- Conditions
- Breast Cancer
- Interventions
- cyclophosphamide, docetaxel, doxorubicin
- Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 5,351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2012
- U.S. locations
- 146
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 123 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 7,237
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Tarceva, carboplatin, paclitaxel
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 38
- States / cities
- Alhambra, California • Bakersfield, California • Concord, California + 31 more
- Conditions
- Advanced Malignancies
- Interventions
- CDX-1401 in combination with Resiquimod and/or Poly-ICLC, CDX-1401, Resiquimod, poly-ICLC
- Biological
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 7
- States / cities
- New Haven, Connecticut • Miami Beach, Florida • Detroit, Michigan + 3 more
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
- Interventions
- Cohort B: paridiprubart, Cohort B: placebo
- Drug
- Lead sponsor
- PPD Development, LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more
- Conditions
- Sleep Apnea, Elderly Adults
- Interventions
- Hyperoxia/oxygen, Acetazolamide, Finasteride
- Other · Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 60 Years to 89 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Hepatitis C Virus (HCV)
- Interventions
- Pegylated interferon lambda (pegIFNλ), Pegylated interferon alfa-2a (pegIFNα-2a), Ribavirin, Daclatasvir, Placebo matching Daclatasvir
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 880 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • San Diego, California • San Francisco, California + 12 more
- Conditions
- Hyperparathyroidism, Secondary
- Interventions
- Etelcalcetide, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 45
- States / cities
- Mobile, Alabama • Azusa, California • Beverly Hills, California + 42 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- XL184
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 5 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin, ritonavir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Anaheim, California • Coronado, California + 11 more
- Conditions
- Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma
- Interventions
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Tivantinib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 214
- States / cities
- Tucson, Arizona • Anaheim, California • Baldwin Park, California + 154 more
- Conditions
- Febrile Neutropenia, Stage 0 Breast Cancer, Stage 0 Colorectal Cancer, Stage 0 Non-Small Cell Lung Cancer, Stage I Colorectal Cancer, Stage IA Breast Cancer, Stage IA Non-Small Cell Lung Carcinoma, Stage IB Breast Cancer, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Breast Cancer, Stage IIA Colorectal Cancer, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Breast Cancer, Stage IIB Colorectal Cancer, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIC Colorectal Cancer, Stage IIIA Breast Cancer, Stage IIIA Colorectal Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Colorectal Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IIIC Colorectal Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
- Interventions
- Preventive Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 3,665 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 159
- States / cities
- Jonesboro, Arkansas • Martinez, California • Augusta, Georgia + 134 more
- Conditions
- Physiological Stress
- Interventions
- Exercise, Stress Management, Exercise and Stress Management, Standard Care
- Behavioral · Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 19
- States / cities
- Duarte, California • Gainesville, Florida • Tampa, Florida + 15 more
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma, Ann Arbor Stage III Lymphoma, Ann Arbor Stage IV Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Gastroesophageal Junction Adenocarcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Breast Carcinoma, Kidney Carcinoma, Malignant Hepatobiliary Neoplasm, Malignant Solid Neoplasm, Melanoma, Muscle-Invasive Bladder Carcinoma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma, RISS Stage III Plasma Cell Myeloma, Sarcoma, Stage I Bladder Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Esophageal Cancer AJCC V7, Stage I Gastric Cancer AJCC V7, Stage I Lung Cancer AJCC v7, Stage I Ovarian Cancer AJCC v6 and v7, Stage I Pancreatic Cancer AJCC v6 and v7, Stage I Prostate Cancer AJCC v7, Stage I Uterine Corpus Cancer AJCC v7, Stage II Bladder Cancer AJCC v6 and v7, Stage II Breast Cancer AJCC v6 and v7, Stage II Colorectal Cancer AJCC v7, Stage II Esophageal Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage II Lung Cancer AJCC v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage II Prostate Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage III Bladder Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Bladder Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Stage IV Lung Cancer AJCC v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Thyroid Gland Carcinoma
- Interventions
- Questionnaire Administration, Biospecimen Collection
- Other · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 747
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 502 more
- Conditions
- Deep Venous Thrombosis
- Interventions
- Not listed
- Lead sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 803 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Durham, North Carolina • Oklahoma City, Oklahoma
- Conditions
- Pneumococcal Infections
- Interventions
- V114, Prevnar 13™
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 6
- States / cities
- Wilmington, Delaware • Atlanta, Georgia • Detroit, Michigan + 3 more
- Conditions
- Acne Vulgaris
- Interventions
- Olumacostat Glasaretil Gel, 5.0%, Olumacostat Glasaretil Gel, Vehicle
- Drug · Other
- Lead sponsor
- Dermira, Inc.
- Industry
- Eligibility
- 9 Years and older
- Enrollment
- 744 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 36
- States / cities
- Guntersville, Alabama • Glendale, Arizona • Bryant, Arkansas + 32 more
- Conditions
- Solid Tumors
- Interventions
- ABT-263, erlotinib, irinotecan (3-week schedule), irinotecan (weekly schedule)
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 4
- States / cities
- Santa Monica, California • Detroit, Michigan • San Antonio, Texas + 1 more
- Conditions
- Sickle Cell Disease
- Interventions
- Tebapivat, Tebapivat Matched Placebo
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 10
- States / cities
- Farmington, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
- Interventions
- Cetuximab, Encorafenib, Nivolumab
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 282
- States / cities
- Goodyear, Arizona • Carmichael, California • Dublin, California + 223 more
- Conditions
- Multiple Sclerosis
- Interventions
- other disease-modifying therapy, Fingolimod
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 3,076 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 208
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 181 more
- Conditions
- Lung Cancer
- Interventions
- Celecoxib, Docetaxel
- Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Diabetes, Diabetes Mellitus, Type 1
- Interventions
- insulin detemir, insulin glargine, insulin aspart
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 28
- States / cities
- Anaheim, California • Huntington Beach, California • Inglewood, California + 24 more
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 188
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 158 more
- Conditions
- Atopic Dermatitis
- Interventions
- tapinarof cream, 1%, vehicle cream
- Drug
- Lead sponsor
- Organon and Co
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 49 more